The aim of this observational study is to investigate the survival differences among patients with non-small cell lung cancer who received different adjuvant treatments after neoadjuvant immunotherapy, and to identify the main clinical characteristics of these survival differences. The main question it aims to answer is: 1. Is there a difference in survival between patients who achieve pCR after neoadjuvant immunotherapy and those who do not receive adjuvant therapy? 2. What are the recurrence patterns and high-risk factors for recurrence in patients with pCR after neoadjuvant immunotherapy, and how can early intervention be carried out? 3. Is there a difference in survival among patients with non-MPR after neoadjuvant immunotherapy when they receive different adjuvant treatment modalities (single immunotherapy, chemio-immunotherapy, chemotherapy, etc.)? 4. Should patients with non-MPR after neoadjuvant immunotherapy continue immunotherapy, and what are the predictive markers for receiving adjuvant therapy?
The aim of this observational study is to investigate the survival differences among patients with non-small cell lung cancer who received different adjuvant treatments after neoadjuvant immunotherapy, and to identify the main clinical characteristics of these survival differences. The main question it aims to answer is: 1. Is there a difference in survival between patients who achieve pCR after neoadjuvant immunotherapy and those who do not receive adjuvant therapy? 2. What are the recurrence patterns and high-risk factors for recurrence in patients with pCR after neoadjuvant immunotherapy, and how can early intervention be carried out? 3. Is there a difference in survival among patients with non-MPR after neoadjuvant immunotherapy when they receive different adjuvant treatment modalities (single immunotherapy, chemio-immunotherapy, chemotherapy, etc.)? 4. Should patients with non-MPR after neoadjuvant immunotherapy continue immunotherapy, and what are the predictive markers for receiving adjuvant therapy? Participants will undergo neoadjuvant immunotherapy and surgical procedures, and through rigorous analysis of real-world data, this study endeavors to provide nuanced insights into these fundamental queries, fostering advancements in clinical decision-making and patient management strategies.
Study Type
OBSERVATIONAL
Enrollment
10,000
Adjuvant PD-1 inhibitor maintenance therapy
Postoperative chemotherapy as an adjuvant treatment
Postoperative PD-1 inhibitor combined with chemotherapy as adjuvant therapy
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Overall Survival (OS)
OS is defined as the time from surgery time until death from any cause.
Time frame: From date of diagnosis until the date of death from any cause, whichever came first, assessed up to 7 years and 11 months.
Event-free survival(EFS)
Event-free survival was defined as the time from neoadjuvant treatment to metastasis or death by any cause in the absence of metastasis.
Time frame: up to 7 years and 11 months.
Pathological Complete Response(pCR)
After evaluating the removed tumor tissue and the regional lymph nodes, no residual tumor cells were found.
Time frame: up to 1 month after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.